BIG growth for German group

Dr Mani Herold, CFO of the Rodenstock Group

Driven by continuously growing demand for its BIG Vision product portfolio of biometric progressive lenses, as well as the successful launch of its BIG Norm lens range in 2022, the Rodenstock Group has increased consolidated pro-forma net sales to 505 million euros (previous year 486 million euros on a like-for-like basis).

Despite a slow-down in sales growth in the second half of 2022, Rodenstock generated recurring EBITDA of 118 million euros in 2022 – down four per cent compared to previous year on a like-for like basis, considering the transfer of the Russian business during the year and the deconsolidation of the eyewear business.

Marcus Desimoni, CEO of the Rodenstock Group, remarked: “Despite substantial market headwinds, we have successfully continued to execute on our BIG Vision strategy and expanded our global lenses business. I would like to thank the entire team for their hard work and commitment over the past year. Strategic milestones such as the acquisition of Indo Optical and the sale of the eyewear business have provided the basis for further profitable growth in the coming years.”

Dr Mani Herold, CFO of the Rodenstock Group, added: “2022 was marked by important strategic decisions for group. I am thrilled to be part of Rodenstock as we are entering the next phase of our transformation into a leading Med-Tech company and to support our worldwide organization in delivering strong growth whilst focusing on superior financial performance and operational excellence.”

The company added that the leadership team would maintain the strategic direction of the group and continue to invest in R&D, products and services portfolio and its state-of-the-art production facilities.